Savira Feby, Cao Longxing, Wang Ian, Yang Wendi, Huang Kevin, Hua Yue, Jucker Beat M, Willette Robert N, Huang Li, Krum Henry, Li Zhiliang, Fu Qiang, Wang Bing Hui
Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Zhujiang Hospital, School of Medicine, Southern Medical University, Guangzhou, China.
PLoS One. 2017 Nov 6;12(11):e0187459. doi: 10.1371/journal.pone.0187459. eCollection 2017.
Intracellular accumulation of protein-bound uremic toxins in the setting of cardiorenal syndrome leads to adverse effects on cardiorenal cellular functions, where cardiac hypertrophy and cardiorenal fibrosis are the hallmarks. In this study, we sought to determine if Apoptosis Signal-Regulated Kinase 1 (ASK1), an upstream regulator of cellular stress response, mediates cardiac hypertrophy and cardiorenal fibrosis induced by indoxyl sulfate (IS) and p-cresol sulfate (PCS) in vitro, and whether ASK1 inhibition is beneficial to ameliorate these cellular effects. PCS augmented cardiac myocyte hypertrophy and fibroblast collagen synthesis (as determined by 3H-leucine and 3H-proline incorporation, respectively), similar to our previous finding with IS. IS and PCS also increased collagen synthesis of proximal tubular cells and renal mesangial cells. Pro-hypertrophic (α-skeletal muscle actin and β-MHC) and pro-fibrotic genes (TGF-β1 and ctgf) were induced by both IS and PCS. Western blot analyses revealed the activation of ASK1 and downstream mitogen activated protein kinases (MAPKs) (p38MAPK and ERK1/2) as well as nuclear factor-kappa B (NF-κB) by IS and PCS. ASK1, OAT1/3, ERK1/2 and p38MAPK inhibitors suppressed all these effects. In summary, IS and PCS exhibit pro-hypertrophic and pro-fibrotic properties, at least in part, via the activation of ASK1 and its downstream pathways. ASK1 inhibitor is an effective therapeutic agent to alleviate protein-bound uremic toxin-induced cardiac hypertrophy and cardiorenal fibrosis in vitro, and may be translated further for cardiorenal syndrome therapy.
在心肾综合征背景下,蛋白结合型尿毒症毒素的细胞内蓄积会对心肾细胞功能产生不良影响,其特征为心脏肥大和心肾纤维化。在本研究中,我们试图确定细胞应激反应的上游调节因子凋亡信号调节激酶1(ASK1)是否在体外介导硫酸吲哚酚(IS)和对甲酚硫酸酯(PCS)诱导的心脏肥大和心肾纤维化,以及抑制ASK1是否有利于改善这些细胞效应。与我们之前对IS的研究结果相似,PCS增加了心肌细胞肥大和成纤维细胞胶原蛋白合成(分别通过3H-亮氨酸和3H-脯氨酸掺入法测定)。IS和PCS还增加了近端肾小管细胞和肾系膜细胞的胶原蛋白合成。IS和PCS均诱导了促肥大基因(α-骨骼肌肌动蛋白和β-心肌肌球蛋白重链)和促纤维化基因(转化生长因子-β1和结缔组织生长因子)。蛋白质印迹分析显示,IS和PCS激活了ASK1及其下游的丝裂原活化蛋白激酶(MAPK)(p38MAPK和ERK1/2)以及核因子-κB(NF-κB)。ASK1、OAT1/3、ERK1/2和p38MAPK抑制剂均抑制了所有这些效应。总之,IS和PCS至少部分通过激活ASK1及其下游途径表现出促肥大和促纤维化特性。ASK1抑制剂是一种有效的治疗药物,可在体外减轻蛋白结合型尿毒症毒素诱导的心脏肥大和心肾纤维化,并且可能进一步转化用于心肾综合征的治疗。